Goodbody Health Limited (GDBYF) Aktienanalyse
Nur zu Informationszwecken. Keine Finanzberatung. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Mit einem Kurs von $ ist Goodbody Health Limited (GDBYF) ein Healthcare-Unternehmen mit einer Bewertung von 0. Die Aktie erzielt 61/100, eine moderate Bewertung basierend auf 9 quantitativen KPIs.
Zuletzt analysiert: 16. März 2026Goodbody Health Limited (GDBYF) Gesundheitswesen & Pipeline-Uebersicht
Goodbody Health Inc. is a UK-focused wellness company operating as a vertically integrated cannabinoid (CBD) business. Their activities encompass CBD extraction, wholesale, retail, and research. With a presence in the UK and EU, Goodbody Health also has interests in COVID and blood testing, positioning them in the specialty drug and wellness market.
Investmentthese
Goodbody Health Inc. presents a speculative investment opportunity within the evolving CBD market in the UK and EU. The company's vertical integration offers potential for margin control and supply chain efficiencies. However, the company's negative profit margin of -13.6% indicates challenges in achieving profitability. Growth catalysts include expansion of their retail CBD offerings and progress in medicinal cannabis research programs. Key risks include regulatory uncertainties surrounding the CBD market and competition from established players. Investors should carefully consider the company's financial performance and the volatile nature of the CBD industry before investing. The high beta of 9.86 suggests significant price volatility relative to the market.
Basierend auf FMP-Finanzdaten und quantitativer Analyse
Wichtige Highlights
- Vertically integrated cannabinoid (CBD) business operating in the UK and EU, providing control over the supply chain from extraction to retail sales.
- Involvement in COVID and blood testing clinics, diversifying revenue streams beyond CBD products.
- Gross margin of 52.4% indicates potential for profitability if operating expenses can be managed effectively.
- Active in medicinal cannabis research programs, positioning the company to capitalize on potential regulatory changes and market expansion.
- Headquartered in Vancouver, Canada, but primarily focused on the UK and EU markets, providing exposure to international growth opportunities.
Wettbewerber & Vergleichsunternehmen
Staerken
- Vertically integrated CBD business model.
- Presence in the UK and EU markets.
- Diversified revenue streams with COVID and blood testing clinics.
- Involvement in medicinal cannabis research programs.
Schwaechen
- Negative profit margin (-13.6%).
- Reliance on the evolving and uncertain CBD market.
- Limited brand recognition compared to larger competitors.
- Potential regulatory challenges in the CBD and cannabis industries.
Katalysatoren
- Upcoming: Potential regulatory changes in the UK and EU regarding CBD and cannabis products could significantly impact the company's market access and growth prospects.
- Ongoing: Expansion of the company's retail CBD product line and market reach.
- Ongoing: Progress in medicinal cannabis research programs and potential development of novel therapies.
- Ongoing: Strategic partnerships and acquisitions to expand product portfolio and market access.
Risiken
- Potential: Regulatory uncertainties surrounding the CBD market in the UK and EU could negatively impact the company's operations and financial performance.
- Ongoing: Intense competition in the CBD market from established players and new entrants.
- Potential: Fluctuations in raw material prices could affect the company's gross margins.
- Ongoing: The company's negative profit margin (-13.6%) poses a risk to its long-term financial sustainability.
- Potential: Changes in consumer preferences and trends could impact demand for the company's products.
Wachstumschancen
- Expansion of Retail CBD Offerings: Goodbody Health can expand its retail CBD product line to cater to a broader range of consumer needs and preferences. The global CBD market is projected to reach billions of dollars in the coming years, offering significant growth potential for companies with strong retail presence and brand recognition. Timeline: Ongoing, with continuous product development and marketing efforts.
- Development of Medicinal Cannabis Research Programs: Investing in medicinal cannabis research programs can lead to the development of novel therapies and intellectual property, positioning Goodbody Health to capitalize on potential regulatory changes and market expansion in the medicinal cannabis sector. The market for medicinal cannabis is expected to grow significantly as more countries legalize and regulate its use. Timeline: Medium-term, with research and development efforts spanning several years.
- Geographic Expansion within the EU: Expanding its operations to other EU countries can provide access to new markets and customer bases, driving revenue growth and diversification. The European CBD market is fragmented, with varying regulatory frameworks across different countries, presenting both opportunities and challenges for expansion. Timeline: Medium-term, with market research and regulatory compliance efforts required.
- Strategic Partnerships and Acquisitions: Forming strategic partnerships with other companies in the healthcare and wellness sectors can provide access to new technologies, distribution channels, and customer segments. Acquisitions of complementary businesses can further expand Goodbody Health's product portfolio and market reach. Timeline: Ongoing, with continuous evaluation of potential partnership and acquisition opportunities.
- White Label and Wholesale Expansion: Increasing white label and wholesale sales of CBD isolate and distillate can provide a stable revenue stream and leverage the company's extraction capabilities. The demand for high-quality CBD ingredients is growing among manufacturers of CBD-infused products, creating opportunities for Goodbody Health to expand its wholesale business. Timeline: Ongoing, with sales and marketing efforts targeting potential white label and wholesale customers.
Chancen
- Expansion of retail CBD product offerings.
- Geographic expansion within the EU.
- Development of novel therapies through medicinal cannabis research.
- Strategic partnerships and acquisitions.
Risiken
- Intense competition in the CBD market.
- Regulatory changes and uncertainties.
- Fluctuations in raw material prices.
- Changing consumer preferences and trends.
Wettbewerbsvorteile
- Vertical Integration: Controlling the entire CBD supply chain from extraction to retail provides cost advantages and quality control.
- Established Presence in the UK and EU: Having an existing operational footprint in these markets provides a competitive advantage over new entrants.
- Diversified Revenue Streams: Involvement in COVID and blood testing clinics diversifies revenue beyond CBD products.
- Medicinal Cannabis Research Programs: Investing in research can lead to proprietary formulations and intellectual property.
Ueber GDBYF
Goodbody Health Inc., formerly Sativa Wellness Group Inc., is a wellness company providing a range of health and wellness products and services in the United Kingdom. Founded with a vision to capitalize on the burgeoning CBD market, the company has evolved into a vertically integrated cannabinoid business operating in both the UK and the European Union. Goodbody Health's operations span multiple segments of the CBD value chain, including CBD extraction, wholesale bulk isolate and distillate sales, retail CBD product sales, and white label sales. Additionally, the company has interests in COVID and blood testing clinics, reflecting a diversification strategy within the broader healthcare sector. Goodbody Health also engages in cannabinoid laboratory testing and medicinal cannabis research programs. The company's headquarters are located in Vancouver, Canada, while its primary operational focus remains in the UK and EU markets. The rebranding from Sativa Wellness Group Inc. to Goodbody Health Inc. in January 2022 signifies a strategic shift towards a more comprehensive health and wellness focus.
Was das Unternehmen tut
- Provides health and wellness products and services in the United Kingdom.
- Operates as a vertically integrated cannabinoid (CBD) company.
- Engages in CBD extraction and wholesale bulk isolate and distillate sales.
- Sells retail CBD products and offers white label sales.
- Conducts cannabinoid laboratory testing.
- Participates in medicinal cannabis research programs.
- Operates COVID and blood testing clinics.
Geschaeftsmodell
- Generates revenue through the sale of CBD products in retail channels.
- Earns revenue from wholesale sales of CBD isolate and distillate to other manufacturers.
- Provides white label CBD products to other companies for resale under their own brands.
- Offers COVID and blood testing services through its clinics.
Branchenkontext
Goodbody Health operates within the rapidly evolving specialty and generic drug manufacturing industry, specifically focusing on the cannabinoid (CBD) market. The global CBD market is experiencing significant growth, driven by increasing consumer awareness and acceptance of CBD products for various health and wellness applications. However, the industry is also characterized by regulatory uncertainty and intense competition. Goodbody Health's vertical integration strategy aims to provide a competitive advantage in this dynamic landscape. The company's involvement in COVID and blood testing clinics further diversifies its revenue streams within the broader healthcare sector.
Wichtige Kunden
- Individual consumers seeking health and wellness products, particularly CBD-based products.
- Other companies in the health and wellness industry that purchase CBD isolate and distillate for use in their own products.
- Businesses that require white label CBD products for resale under their own brands.
- Individuals seeking COVID and blood testing services.
Finanzdaten
Chart & Info
Goodbody Health Limited (GDBYF) Aktienkurs: Price data unavailable
Aktuelle Nachrichten
Keine aktuellen Nachrichten fuer GDBYF verfuegbar.
Analystenkonsens
Konsens-Bewertung
Aggregierte Kauf-/Halten-/Verkauf-Empfehlungen von Benzinga, Yahoo Finance und Finnhub fuer GDBYF.
Kursziele
Wall-Street-Kurszielanalyse fuer GDBYF.
MoonshotScore
Was bedeutet diese Bewertung?
Der MoonshotScore bewertet das Wachstumspotenzial von GDBYF auf einer Skala von 0-100 ueber mehrere Faktoren wie Innovation, Marktdisruption, finanzielle Gesundheit und Momentum.
Fuehrung: Geremy Howard Prance Thomas
CEO
Geremy Howard Prance Thomas serves as the Chief Executive Officer of Goodbody Health Inc. His background includes experience in the health and wellness sector, with a focus on developing and scaling businesses in emerging markets. He has a track record of leading companies through periods of growth and transformation. His expertise spans strategic planning, operational execution, and financial management. He brings a wealth of knowledge in navigating complex regulatory environments and building strong relationships with stakeholders.
Erfolgsbilanz: Under Geremy Howard Prance Thomas's leadership, Goodbody Health Inc. has focused on expanding its vertical integration within the CBD market and diversifying its revenue streams through COVID and blood testing clinics. Key milestones include the rebranding from Sativa Wellness Group Inc. to Goodbody Health Inc. and the continued development of medicinal cannabis research programs. His strategic decisions have aimed to position the company for long-term growth in the evolving health and wellness landscape.
GDBYF OTC-Marktinformationen
The OTC Other tier represents the lowest tier of the OTC market, indicating that Goodbody Health Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited information available to investors, and trading activity can be sporadic. Investing in OTC Other stocks carries higher risks compared to stocks listed on major exchanges like the NYSE or NASDAQ due to less stringent regulatory oversight and potential for information asymmetry.
- OTC-Stufe: OTC Other
- Offenlegungsstatus: Unknown
- Limited Financial Disclosure: Lack of readily available financial information increases investment risk.
- Low Liquidity: Difficulty in buying or selling shares due to low trading volume.
- Potential for Information Asymmetry: Limited information available to investors compared to companies listed on major exchanges.
- Higher Price Volatility: OTC stocks are generally more volatile than stocks listed on major exchanges.
- Regulatory Uncertainty: OTC-listed companies are subject to less regulatory oversight.
- Verify the company's financial statements and audit reports.
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's regulatory compliance and legal risks.
- Monitor trading volume and bid-ask spreads to assess liquidity.
- Consult with a financial advisor before investing.
- Understand the risks associated with investing in OTC stocks.
- Operational Business: The company has ongoing business operations in the health and wellness sector.
- Vertical Integration: The company's vertical integration in the CBD market can be a positive sign.
- Website and Public Information: The company maintains a website and provides some public information about its business.
- CEO Leadership: The company has an identified CEO in Geremy Howard Prance Thomas.
Haeufige Fragen zu GDBYF
What are the key factors to evaluate for GDBYF?
Goodbody Health Limited (GDBYF) currently holds an AI score of 61/100, indicating moderate score. Key strength: Vertically integrated CBD business model.. Primary risk to monitor: Potential: Regulatory uncertainties surrounding the CBD market in the UK and EU could negatively impact the company's operations and financial performance.. This is not financial advice.
How frequently does GDBYF data refresh on this page?
GDBYF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven GDBYF's recent stock price performance?
Recent price movement in Goodbody Health Limited (GDBYF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Vertically integrated CBD business model.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider GDBYF overvalued or undervalued right now?
Determining whether Goodbody Health Limited (GDBYF) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying GDBYF?
Before investing in Goodbody Health Limited (GDBYF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding GDBYF to a portfolio?
Potential reasons to consider Goodbody Health Limited (GDBYF) depend on individual investment goals and risk tolerance. A key strength identified by analysis: Vertically integrated CBD business model.. Additionally: Presence in the UK and EU markets.. The AI-driven MoonshotScore of 61/100 reflects solid quantitative fundamentals. Always weigh potential rewards against risks and diversify across holdings. This is not financial advice.
Can I buy fractional shares of GDBYF?
Yes, most major brokerages offer fractional shares of Goodbody Health Limited (GDBYF) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track GDBYF's earnings and financial reports?
Goodbody Health Limited (GDBYF) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Setting up alerts through your brokerage for GDBYF earnings announcements is recommended.
Haftungsausschluss: Dieser Inhalt dient ausschliesslich zu Informationszwecken und stellt keine Anlageberatung dar. Fuehren Sie immer Ihre eigene Recherche durch und konsultieren Sie einen Finanzberater.
Offizielle Ressourcen
Daten dienen ausschliesslich zu Informationszwecken.
- OTC data may be less reliable than exchange-listed data.
- Limited analyst coverage impacts investment thesis validation.